CB1

The cannabinoid receptor type 1 (CB1) is a G protein-coupled receptor concentrated in the brain and central nervous system, and the primary site through which cannabis exerts its psychoactive effects. It is one component of the broader endocannabinoid system — a signalling network that helps regulate mood, memory, appetite, pain, and many other functions.

CB1 receptors are among the most abundant G protein-coupled receptors in the brain. They are found in especially high density in the basal ganglia, cerebellum, hippocampus, and prefrontal cortex — regions involved in movement, coordination, memory, and executive function. This distribution maps closely onto the specific cognitive and motor effects that cannabinoids produce.

How it works · its role

CB1 is coupled to inhibitory G proteins, meaning that when it is activated, it generally suppresses neuronal activity. It does this primarily by reducing neurotransmitter release at the synapse — dampening signals from both excitatory and inhibitory neurons depending on where it sits.

The body produces its own molecules that activate CB1, called endocannabinoids. The two best-characterised are anandamide and 2-arachidonoylglycerol (2-AG). Unlike most neurotransmitters, endocannabinoids travel backwards across the synapse — from the receiving cell to the sending cell — allowing neurons to modulate how strongly they are being driven. CB1 activation is, in this sense, a volume-control mechanism built into the brain.

Relevance to substances & effects

THC (tetrahydrocannabinol), the principal psychoactive compound in cannabis, binds CB1 as a partial agonist. This produces the effects most associated with cannabis: euphoria, altered sensory perception, impaired short-term memory, increased appetite, reduced nausea, and analgesia.

Synthetic cannabinoids — sometimes sold as herbal incense products — act as full agonists at CB1, binding more completely and with greater potency than THC. Because full agonism drives stronger receptor activation, these compounds tend to produce more intense and less predictable effects, with a higher likelihood of adverse reactions including anxiety, psychosis-like states, and cardiovascular stress.

Some substances interact with CB1 indirectly. CBD (cannabidiol) has low direct affinity for the receptor but influences its signalling environment through other mechanisms, which is thought to partly explain its moderating effect on THC's psychoactivity.

Tolerance & dependence

With repeated or heavy stimulation, CB1 receptors respond through two processes: desensitisation (reduced responsiveness to activation) and downregulation (a reduction in the total number of available receptors). Together, these are the primary mechanism behind cannabis tolerance — why the same dose produces smaller effects over time.

This downregulation reverses with abstinence. Research in regular cannabis users suggests partial recovery of CB1 receptor density within days to weeks of stopping, which broadly tracks the timescale on which tolerance fades.

The same receptor-level adaptation underpins the physical dependence that can develop with prolonged heavy use. When CB1 stimulation is abruptly withdrawn, the now-suppressed signalling network can produce a withdrawal state characterised by irritability, sleep disruption, and reduced appetite — roughly the inverse of the receptor's activated effects.